Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06235580

Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions

Over the past twenty years, Prof. Yanick Crow and his team have developed internationally recognized expertise in genetic pathologies affecting the immune and neurological systems. The pathologies studied have a particularly severe impact on patients' quality of life, with a high mortality rate and a significant risk of occurrence in affected families. These pathologies are rare, and very often under-diagnosed. To date, there is virtually no effective curative treatment.

Prof. Crow's team operates at the frontier between clinical and research work, and from experience, the team knows that patients and families affected by these serious pathologies are often highly motivated to help research into the pathology that affects them.

Initially, Prof. Crow's research focused primarily on the study of the genetic disease Aicardi-Goutières Syndrome (AGS). However, there is an undeniable clinical and pathological overlap between AGS and other forms of disease such as autoimmune systemic lupus erythematosus and many other genetic pathologies - e.g. familial lupus engelure, spondyloenchondromatosis and COPA syndrome. This is why research is being extended to all genetic diseases with immune and neurological dysfunctions.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Necker enfants malades Hospital

Paris, Île-de-France Region, 75015, France

Location status: Recruiting

Location contact

Marie-Louise Frémond, MD, PhD

CONTACT

[email protected]

Yannick Crow, MD PhD

CONTACT

[email protected]

About this study

The research methodology is classic with regard to many genetic clinical studies, and aims to:

  • clinically define the phenotypes of these diseases (in this case, genetic diseases with immune and neurological dysfunctions)
  • identify the gene(s) responsible for each disease
  • Understand how changes in these genes and protein functions cause these diseases.

It is possible that this research will ultimately lead to the creation of diagnostic tests (e.g. molecular diagnostic screening tests) and treatments that would be clinically very useful for the patients participating in the project. These discoveries could also improve our knowledge of other more common pathologies, particularly those associated with autoimmunity (e.g. when the body increases an immune response against its own tissues).

As a complement to this global research project, Prof. Crow's team intends to study cell populations from patients with no inflammatory pathology, in order to analyze their basal levels of immune and inflammatory mediator production, as well as to assess their capacity (kinetics and amplitude) to respond to stimuli.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients :
  • Have / present a family history of genetic disease with immune and neurological dysfunction.
  • Have signed an informed consent form.
  • Unaffected related subjects :
  • Be related to a patient included in this research.
  • Have signed an informed consent form.
  • Control patients
  • Be free of any genetic disease with immune and neurological dysfunction.
  • Have undergone surgery as part of their management
  • Have signed an informed consent form.

Non-inclusion criteria

✓ Be deprived of liberty

Treatment and study plan

Biological Samples

Other

For patients, different types of banked frozen or fresh biological samples will be used in this research:

  • Blood
  • Skin biopsy or other tissues (liver, muscle, brain, lung...)
  • Urine
  • Saliva
  • Cerebrospinal fluid
  • Occasionally: operative "leftovers" (e.g. muscle, brain, lung tissue)

In control patients, we would like to collect operative remnants of cell types involved in the inflammatory and/or neurological diseases studied in the laboratory, if these patients require surgery as part of their management, and if any biological material remains after surgery. Under the same conditions, a sample of cerebrospinal fluid could be recovered.

For unaffected relatives, a single blood sample of maximum 10 ml is taken at inclusion, and samples already taken during routine care are used.

Primary outcomes

  1. Clinical features of human genetic diseases that affect the immune and neurological systems.

    Time frame: through study completion, an average of 1 year

    Clinical features of human genetic diseases that affect the immune and neurological systems.

  2. Natural history of human genetic diseases that affect the immune and neurological systems.

    Time frame: through study completion, an average of 1 year

    Natural history of human genetic diseases that affect the immune and neurological systems.

  3. Molecular and cellular basis of human genetic diseases that affect the immune and neurological systems.

    Time frame: through study completion, an average of 1 year

    Molecular and cellular basis of human genetic diseases that affect the immune and neurological systems.

Study contacts

Contact information is provided by the study sponsor or research team.

Marie-Louise Frémond, MD PhD

CONTACT

[email protected]

Yanick Crow, MD PhD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Imagine Institute

Other

Registry information

Acronym: IFN

Important dates

Study start
2015
Primary completion
2030
Study completion
2035
First posted
Feb 1, 2024
Registry last updated
Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.